# DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

> **NCT05770102** · PHASE2,PHASE3 · RECRUITING · sponsor: **Cancer Research UK** · enrollment: 30 (estimated)

## Conditions studied

- Malignancy
- Malignant Neoplasm
- Lymphoproliferative Disorders
- Neoplasms by Histologic Type
- Neoplasms by Site
- Cancer
- Colorectal Neoplasms
- Endometrial Neoplasms
- Melanoma
- Solid Tumours

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT05770102
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-25
- **Primary completion:** 2029-10
- **Final completion:** 2029-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05770102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05770102, "DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05770102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*